α2-AR uniquely exert an inhibitory regulation of both Arc and Zif268 compared to α1 and β-AR.
The α2-AR antagonist, RX821002, increases Arc and Zif268 interdependent with α1 and β-AR.
A lack of adult IEG response to combined α1 and β-AR blockade contrasts with decreases to n-(2-chloroethyl)-n-ethyl-2-bromobenzylamine hydrochloride (DSP4).